Dr. Mark D Wolf, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2055 Bloomfield Woods Ct, West Bloomfield, MI 48323 Phone: 248-454-0888 Fax: 248-332-0451 |
Dr. Cheryl A Ruble, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2300 Haggerty Rd, Suite 1010, West Bloomfield, MI 48323 Phone: 248-668-0900 Fax: 248-926-9112 |
Mr. Bruce Eric Ruben, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2300 Haggerty Rd, Suite 1190, West Bloomfield, MI 48323 Phone: 248-624-9800 Fax: 248-624-9828 |
News Archive
The use of antimicrobial impregnated scrubs combined with good hand hygiene is effective in reducing the burden of Methicillin-Resistant Staphylococcus Aureus (MRSA) on healthcare workers' apparel and may potentially play a role in decreasing the risk of MRSA transmission to patients, according to a new study from Virginia Commonwealth University researchers.
To attract patients, hospitals are increasingly posting wait times for their emergency rooms "on billboards, websites, social media outlets like Twitter and in text messages," The Salt Lake Tribune reports. "It's a competitive strategy, but also a tool for bending the wait-time curve and, hopefully, improving patient care, said Mary Joe Jones, chief clinical nursing officer at St. Mark's Hospital in Salt Lake City."
About 50,000 Danish diabetic patients are treated with GLP-1-based medicine. GLP-1 is a hormone that reduces the blood sugar and inhibits the appetite, and it is a frequent treatment for type 2 diabetes and obesity.
Cybex International, Inc., a leading manufacturer of premium exercise equipment, is treading for a cause. Hundreds of the Medway, Massachusetts-based Company's pink 750T treadmills will be moving at varying speeds in fitness clubs and YMCA's across the country beginning today, October 1 – and with a purpose – to raise funds for The Breast Cancer Research Foundation (BCRF).
Amgen announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine.
› Verified 7 days ago